Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey | Zendy

Colin Swenson | Zendy; N. Lapinel | Zendy; Juzar Ali | Zendy

Open Access

Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey

Author(s) -

Colin Swenson,

N. Lapinel,

Juzar Ali

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa079

Subject(s) - medicine , amikacin , inhalation , adverse effect , inhaler , intensive care medicine , dosing , bronchodilator , anesthesia , emergency medicine , antibiotics , asthma , microbiology and biotechnology , biology

Patients with Mycobacterium avium complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events. Most respondents experienced these events, but management through physician-guided measures (eg, bronchodilator use, oral rinses, and/or temporary dosing adjustments) resulted in symptomatic improvement.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research